Trial · NCT02101268
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Splenic Response Rate at Week 24 | Momelotinib (MMB) | Responder | 7 | Participants | |
| Splenic Response Rate at Week 24 | Best Available Therapy (BAT) | Responder | 3 | Participants | |
| Splenic Response Rate at Week 24 | Momelotinib (MMB) | Nonresponder | 97 | Participants | |
| Splenic Response Rate at Week 24 | Best Available Therapy (BAT) | Nonresponder | 49 | Participants | |
| Total Symptom Score (TSS) Response Rate at Week 24 | Momelotinib (MMB) | Responder | 27 | Participants | |
| Total Symptom Score (TSS) Response Rate at Week 24 | Best Available Therapy (BAT) | Responder | 3 | Participants | |
| Total Symptom Score (TSS) Response Rate at Week 24 | Momelotinib (MMB) | Nonresponder | 76 | Participants | |
| Total Symptom Score (TSS) Response Rate at Week 24 | Best Available Therapy (BAT) | Nonresponder | 48 | Participants | |
| Rate of Red Blood Cell (RBC) Transfusion in the Randomized Treatment Phase, (the Average Number of RBC Units Transfused Per Month Not Associated With Overt Bleeding) | Momelotinib (MMB) | 0.5 | Inter-Quartile Range 0.0 to 2.4 | units/month | |
| Rate of Red Blood Cell (RBC) Transfusion in the Randomized Treatment Phase, (the Average Number of RBC Units Transfused Per Month Not Associated With Overt Bleeding) | Best Available Therapy (BAT) | 1.2 | Inter-Quartile Range 0.0 to 2.8 | units/month | |
RBC Transfusion Independence Rate at Week 24, (Defined as Absence of RBC Transfusions and no Hemoglobin Level Below 8 g/dL in the 12 Weeks Prior to Week 24, Excluding Cases Associated With Clinically Overt Bleeding) | Momelotinib (MMB) | Responder | 45 | Participants | |
RBC Transfusion Independence Rate at Week 24, (Defined as Absence of RBC Transfusions and no Hemoglobin Level Below 8 g/dL in the 12 Weeks Prior to Week 24, Excluding Cases Associated With Clinically Overt Bleeding) | Best Available Therapy (BAT) | Responder | 11 | Participants | |
RBC Transfusion Independence Rate at Week 24, (Defined as Absence of RBC Transfusions and no Hemoglobin Level Below 8 g/dL in the 12 Weeks Prior to Week 24, Excluding Cases Associated With Clinically Overt Bleeding) | Momelotinib (MMB) | Nonresponder | 59 | Participants | |
RBC Transfusion Independence Rate at Week 24, (Defined as Absence of RBC Transfusions and no Hemoglobin Level Below 8 g/dL in the 12 Weeks Prior to Week 24, Excluding Cases Associated With Clinically Overt Bleeding) | Best Available Therapy (BAT) | Nonresponder | 41 | Participants | |
| RBC Transfusion Dependence Rate at Week 24 | Momelotinib (MMB) | Dependent | 52 | Participants | |
| RBC Transfusion Dependence Rate at Week 24 | Best Available Therapy (BAT) | Dependent | 33 | Participants | |
| RBC Transfusion Dependence Rate at Week 24 | Momelotinib (MMB) | Nondependent | 52 | Participants | |
| RBC Transfusion Dependence Rate at Week 24 | Best Available Therapy (BAT) | Nondependent | 19 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02101268/results